فعالية و امان استعمال سكروز الحديد الوريدي في معالجة فقر الدم عند مرضى التحال الدموي المزمن

This study was carried out in the Hemolialysis Unit at AL-Assad University Hospital, Lattakia, and included 41 patients on chronic hemodialysis for more than 6 months, treated by erythropoietin for 4 months at least with hemoglobin concentration less than 10 g dl and serum ferritin less than 100 (absolute iron deficiency) at the beginning of the study. All patients received iron sucrose (100 mg once per week for 8 weeks) by slow intravenous injection. We found out that mean hemoglobin level increased from 7.28 to 10.36 (p< 0.001) and mean serum ferritin level increased from 76.36 to 460.53 (p< 0.0001) and none of the patients developed hypersensitivity reactions. We conclude that iron sucrose is effective and safe in hemodialysis patients.